{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
vitamin a palmitate
to a specific field?
Status:
Investigational
Source:
Am J Physiol Gastrointest Liver Physiol. Jun 2006;290(6):G1089-95.: Not Applicable Veterinary clinical trial Completed N/A
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Biologically, methanogens in the colon can use carbon dioxide and hydrogen to produce methane as a by-product. It was previously considered that humans do not utilize methane. However, in a recent study on rodents, results demonstrated that methane could exert anti-inflammatory, anti-oxidant and anti-apoptotic effects. Furthermore, it has bee suggested, that methane-rich saline could be a promising therapeutic agent for clinical treatment of pancreatitis. Methane gas may also be a promising option for the clinical treatment of Acute Lung Injury and Spinal Cord Injury. The exact mechanism underlying the antioxidative, anti-inflammatory, and antiapoptotic activities of methane is not obvious. Different researchers have proposed different hypotheses. Some have hypothesized that methane might accumulate transiently at the interfaces of cell membranes, thereby changing the physicochemical properties or the in-situ functionality of proteins embedded within this environment. Other investigators have suggested that methane could exert effects on membrane channels affecting G-proteins, membrane or receptor-mediated signaling, or acetylcholine-activated ion channel kinetics. It is unknown if mammalian cells contain an oxygenase that is capable of using methane as a substrate, or if the biological effects of methane are caused by the formation of small amounts of the reactive alcohol, methanol, and/or changes in the redox milieu of the cell due to changes in NAD(P)+/NAD(P)H ratio, and whether or not there is a cellular “receptor” for methane. There are also questions remaining around the difference between intraperitoneal vs inhaled administration of methane.
Status:
Investigational
Source:
INN:cyheptamide [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Cyheptamide is anticonvulsant compound, developed by the Canadian company Ayerst Research Laboratories in the 1960s. Oral administration of compound at 14-25 mg/kg protected mice against the tonic phase of pentylenetetrazole convulsion and maximal electroshock seizure. Anticonvulsant activity of cyheptamide was confirmed in initial clinical studies, but the compound was not marketed.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Citenamide is tricyclic drug, an analog of the anticonvulsant cyheptamide.
Status:
Investigational
Source:
NCT04106557: Phase 3 Interventional Completed Primary Disease or Condition Being Studied: Angelman Syndrome (AS)
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Gaboxadol (or THIP) is a direct GABA mimetic ligand at delta-containing receptors. Gaboxadol went into human clinical trials to test if the drug promoted sleep. It was generally well tolerated. Gaboxadol enhances delta power in NREM sleep in humans. Gaboxadol failed in Phase III for sleep studies. The side effects of Gaboxadol have been described as mild and similar in quality to those of other GABA-mimetics. Gaboxadol is in development with Ovid Therapeutics as a treatment for Angelman syndrome, fragile X syndrome and epilepsy.
Status:
Investigational
Source:
Gut. Jan 1975;16(1):33-5.: Not Applicable Human clinical trial Completed Duodenal Ulcer/physiopathology
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Class (Stereo):
CHEMICAL (ACHIRAL)
Ampyrone (4-Aminoantipyrine or AAP) is a metabolite of aminophenazone and is an aromatic substance with analgesic, antipyretic and anti-inflammatory properties. When combined with the antineoplastic agents, ampyrone decreased their genotoxic, mutagenic, apoptotic, and phagocytic effects. However, ampyrone usually produces side effects, such as the risk of agranulocytosis. Although ampyrone is scarcely ever administered as an analgesic because of the potential side effects, as a raw material, it is mostly used to produce ampyrone derivatives, which have better biological activities. In addition, it is used as a reagent for biochemical reactions producing peroxides or phenols and can also be used to detect phenols in the environment. Exposure to ampyrone could induce changes in the enzyme catalase structure and function.
Status:
Investigational
Source:
NCT03560323: Phase 1 Interventional Recruiting Heart Failure
(2019)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Investigational
Source:
Invest New Drugs. Feb 1990;8(1):113-9.: Phase 2 Human clinical trial Completed Soft Tissue Neoplasms
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Excipient
Source:
0.09%w/v INFILTRATION INJECTABLE, LIPOSOMAL
Source URL:
Class (Stereo):
CHEMICAL (MIXED)
DIPALMITOYLPHOSPHATIDYLGLYCEROL (DPPG) is a phosphatidylglycerol in which the phosphatidyl acyl groups are both palmitoyl. DPPG is one of the commonly used lipids in liposome studies and biological systems research.
Status:
Designated
Source:
FDA ORPHAN DRUG:917622
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
